Clinical impact of <sup>18</sup> F-FDG positron emission tomography/CT on adenoid cystic carcinoma of the head and neck.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 27726225.
- Also identified by DOI 10.1002/hed.24605.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this retrospective study was to assess the diagnostic value of <sup>18</sup> F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT and the prognostic value of metabolic PET parameters in patients with adenoid cystic carcinoma of the head and neck (ACCHN). Forty patients with newly diagnosed ACCHN were enrolled in this study. We investigated the diagnostic value of <sup>18</sup> F-FDG PET/CT for detecting and staging compared to conventional CT. Kaplan-Meier survival analysis for progression-free survival (PFS) was performed with clinicopathological factors and metabolic PET parameters. The <sup>18</sup> F-FDG PET/CT showed comparable sensitivity (92.3%) to conventional CT for lesion detection, and changed staging and management plan in 6 patients (15.0%). Lower PFS rates were associated with advanced T classification, advanced TNM classification, high maximum standardized uptake value (SUVmax; >5.1), and high total lesion glycolysis (>40.1) of the primary tumor. The <sup>18</sup> F-FDG PET/CT can provide additional information for initial staging, and metabolic PET parameters may serve as prognostic factors of ACCHN. © 2016 Wiley Periodicals, Inc. Head Neck 39: 447-455, 2017.
Medical subject headings
- Carcinoma, Adenoid Cystic
- Fluorodeoxyglucose F18
- Head and Neck Neoplasms
- Positron Emission Tomography Computed Tomography